StockVS

Phaos Technology Holdings (Caym (POAS) Aktienanalyse

Gesundheitswesen

Phaos Technology Holdings (Caym

$2.60

$-0.02 (-0.76%)

Zuletzt aktualisiert: 26. Mai 2026

Kursverlauf

Analyse

Unternehmensübersicht

Phaos Technology Holdings (Cayman) Limited operates within the healthcare sector, specifically focusing on the medical devices industry, where it develops and commercializes advanced microscopy-related solutions, technologies, and products. The company executes its manufacturing and commercialization activities through its subsidiary, Phaos Technology Pte. Ltd., which is headquartered in Singapore. Phaos Technology Holdings (Cayman) Limited currently maintains a market capitalization of $21.93M and employs a workforce of 25 individuals. With a trailing twelve-month revenue of $167,707, the company operates on a micro-cap scale, indicating a small market presence relative to larger established medical device manufacturers. The combination of a $21.93M market cap and revenue figures under $200,000 suggests that the company is in an early-stage development phase or is facing significant headwinds in its commercialization efforts. This limited scale implies that the firm is likely prioritizing product iteration and market entry over profitability or broad market dominance at this specific moment in its lifecycle.

Finanzielle Gesundheit

The company reported a revenue of $167,707 over the trailing twelve-month period, yet this generated a net income of $-5,137,064, revealing a profound structural disconnect between top-line sales and bottom-line profitability. This massive gap between the modest revenue and the substantial net loss highlights an extremely aggressive burn rate or significant one-time expenses that are not proportionate to current sales volumes. The EBITDA for the period stood at $-3,869,313, further emphasizing that the core operational cash generation is insufficient to cover existing costs and capital expenditures. Free cash flow amounted to $-1,657,362, indicating that the company is consuming cash reserves rather than generating liquidity from its primary business operations. Profitability is severely compromised across all metrics, with a gross margin of 22.1%, an operating margin of -1897.8%, and a profit margin of 0.0%, which collectively signal that the company is currently unable to convert its sales into sustainable earnings. On the balance sheet side, the company holds $177,660 in cash against $3.26M in debt, creating a situation where liabilities significantly exceed liquid assets. The debt-to-equity ratio is listed as N/A due to the specific financial structure or lack of equity in the denominator, while the current ratio of 0.40 indicates that current liabilities exceed current assets by more than double. This liquidity position suggests a high risk of short-term solvency challenges unless external financing is secured or operational efficiency improves dramatically. Furthermore, the return on equity stands at -1073.1% and the return on assets at -71.2%, metrics that demonstrate how capital deployed by shareholders and creditors is currently generating substantial negative returns rather than value accretion.

Bewertungsanalyse

Valuation multiples for Phaos Technology Holdings are unavailable in traditional terms, as the P/E ratio (TTM) and forward P/E are both N/A due to the company's lack of net income. The price-to-book ratio is reported at -27.23, a negative figure that typically indicates an accounting anomaly, a distressed state, or a situation where book value is negative, rather than a standard market premium over tangible assets. Instead of earnings-based metrics, investors often look to alternative valuation indicators such as the price-to-sales ratio of 130.77 and an EV/EBITDA of -11.44, both of which suggest the market is pricing the stock based on speculative growth potential rather than current financial performance. The stock price has exhibited significant volatility, with a 52-week high of $7.39 and a 52-week low of $0.53, representing a trading range of over 13-fold. Without a specific current price to calculate the exact percentage distance from these bounds, the asset is understood to trade within this wide band, reflecting high uncertainty regarding its fair value. The beta is listed as N/A, which implies that the stock's price volatility relative to the broader market index cannot be statistically determined due to insufficient trading volume or price data history. These valuation characteristics combined with negative financial multiples underscore the speculative nature of the investment and the absence of traditional valuation anchors.

Growth & Income

The company's revenue growth year-over-year is listed as -93.1%, indicating a severe contraction in sales, while earnings growth is N/A because the company has not posted positive earnings in recent periods. The fact that earnings are not growing faster than revenue is moot given that both metrics are heavily distorted by the loss-making status and the drastic decline in revenue. As a non-dividend payer, Phaos Technology Holdings does not distribute a dividend yield or pays out a payout ratio of 0.0%, meaning all retained earnings are theoretically available for reinvestment, though the company is currently burning cash instead. The overall growth and income profile is characterized by a deep contraction in revenue, a complete absence of profit generation, and a lack of shareholder returns through dividends. This profile suggests a company that is struggling to stabilize its revenue streams and has not yet reached a stage where it can sustainably fund growth or return capital to shareholders.

Vergleich mit Mitbewerbern

Phaos Technology Holdings (Caym (POAS) ist in der Medizinprodukte-Branche tätig. So schneidet das Unternehmen im Vergleich zu seinen nächsten Mitbewerbern nach Marktkapitalisierung ab:

Unternehmen Ticker Marktkapitalisierung KGV
Phaos Technology Holdings (Caym POAS $43.09M N/A
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

Das durchschnittliche KGV der Medizinprodukte-Branche beträgt 60.2x. Phaos Technology Holdings (Caym wird mit einem KGV von N/A gehandelt.

Diese Analyse wurde von KI erstellt und dient nur zu Informationszwecken. Sie stellt keine Finanzberatung dar. Daten können verzögert oder ungenau sein. Führen Sie immer Ihre eigene Recherche durch und konsultieren Sie einen qualifizierten Finanzberater, bevor Sie Anlageentscheidungen treffen.

Über Phaos Technology Holdings (Caym

Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.

Die Unternehmensbeschreibung wird auf Englisch angezeigt.

Website besuchen →

Wichtige Kennzahlen

Marktkapitalisierung
$43.09M
KGV
N/A
52-Wochen-Hoch
$7.39
52-Wochen-Tief
$0.53
Durchschn. Volumen
732.53K

Daten bereitgestellt von Yahoo Finance über yfinance. Täglich aktualisiert.

Unternehmensinfo

Börse
AMEX
Land
Singapore
Mitarbeiter
25